Policy Statements & Letters to Policymakers

For decades, NORD has pursued federal and state policies to improve the lives of Americans impacted by rare diseases. This page is updated daily to provide timely information on our policy efforts. Please contact policy@rarediseases.org if you have questions or need additional information. 

NORD Responds to Proposed Amendments Offered by Health Plans to Step Therapy Provisions of Vermont H.766 (Black)

Published: Apr 18, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Utilization Management

Read full statement >

NORD submits comments to Colorado State, Veterans, and Military Affairs Committee on SB24-203

Published: Apr 17, 2024

Read full statement >

NORD & Patient Organizations Ask Mississippi Governor Tate Reeves to Sign SB2156 MS RDAC Bill Into Law

Published: Apr 4, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD and 34 Patient Organizations Celebrate Biden Administration’s Rule to Protect Patients from Short-Term Health Plans

Published: Mar 28, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD Sends Letter of Support to Vermont Senate Health for H.766 Relating to Step Therapy Reforms

Published: Mar 27, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Utilization Management

Read full statement >

NORD & 22 Patient Organizations Issue Letter of Support & Recommendations for MS RDAC Bills HB616/SB2156

Published: Mar 25, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD Submits Statement for the Record on the LDT Hearing

Published: Mar 21, 2024
Tagged in: Access to Innovative Medicines and Therapies Advancing Rare Disease Research and Regulatory Science

Read full statement >

NORD Signs On To Letter Urging Congress to Swiftly Pass Pharmacy Benefit Manager (PBM) Reforms That Ensure Patient Access to More Affordable Healthcare

Published: Mar 19, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD Issues Letter of Support for Rhode Island S2611/H7822 Regarding Step Therapy Protocols

Published: Mar 18, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Utilization Management

Read full statement >

NORD with the Safe Step Act Ad Hoc Coalition Submit Comments for the Committee’s RFI On The Employee Retirement Income Security Act (ERISA) with Recommendations to Reform Step Therapy and Mark Up Safe Step Act (H.R. 2630)

Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies

Read full statement >

NORD submits comments to CMS in response to the Medicare Prescription Payment Plan (MPPP) Draft Guidance – Part Two

Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Medicare, Medicaid, and Private Health Insurance Coverage Out of Pocket Prescription Drug Costs

Read full statement >

NORD joins coalition of leading patient organizations in submitting comments to CMS on the Medicare Prescription Payment Plan (MPPP) Part 2 Draft Guidance

Published: Mar 15, 2024

Read full statement >

NORD Signs On to A Letter to The Committee on Education and the Workforce Request for Information on Employer-Sponsored Insurance and Employee Retirement Income Security Act (ERISA)

Published: Mar 15, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD Joins Patient Organizations in Support of New Jersey A1825 Establishing Step Therapy Protocols

Published: Mar 13, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Out of Pocket Prescription Drug Costs Utilization Management

Read full statement >

NORD Issues Letter of Support for New Jersey A1825 Regarding Step Therapy Protocols

Published: Mar 13, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Utilization Management

Read full statement >

NORD joins leading patient organizations in submitting comments to CMS on Pennsylvania 1115 waiver

Published: Mar 13, 2024

Read full statement >

NORD Sends Letter of Support to the Vermont House for Provisions of Vermont H.766 Relating to Step Therapy Requirements

Published: Mar 12, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies

Read full statement >

NORD Sends Letter of Support On Tennessee HB1973 – An Act Relative to Newborn Screening

Published: Mar 12, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD Joins California Patient Groups in Support of AB2613 to Create an RDAC in California

Published: Mar 11, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD Submits Testimony on Biomarker Coverage in Nevada

Published: Mar 11, 2024
Tagged in: Access to Innovative Medicines and Therapies

Read full statement >

NORD joins 17 patient organizations in urging CMS to approve Minnesota continuous eligibility amendment

Published: Mar 6, 2024

Read full statement >

NORD joins leading patient organizations in submitting comments to CMS on Hawaii 1115 waiver

Published: Mar 6, 2024

Read full statement >

NORD Supports SB5821 in Washington to Protect Audio-Only Telehealth Services

Published: Mar 5, 2024
Tagged in: Telehealth

Read full statement >

NORD submits letter in support of CT S.B. No. 206, concerning the expansion of the Katie Beckett Waiver program

Published: Mar 5, 2024
Tagged in: Access to Affordable, Adequate Coverage Medicare, Medicaid, and Private Health Insurance Coverage

Read full statement >

NORD Sends a Letter of Support for S.B. No. 175, An Act Concerning Funds for the CT RDAC

Published: Mar 5, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD Joins Michigan-Based and National Organizations Representing Patients and Their Providers Support H.B. 5339 Protect Michiganders from Harmful Step Therapy Protocols

Published: Mar 4, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Utilization Management

Read full statement >

NORD and other stakeholders submit letter to Congress urging passage of the PASTEUR Act

Published: Feb 29, 2024
Tagged in: Funding for Ongoing Science Public Health Research

Read full statement >

NORD submits statement for the record in advance of crucial Rare Disease Day hearing

Published: Feb 28, 2024
Tagged in: Access to Affordable, Adequate Coverage Access to Innovative Medicines and Therapies Advancing Rare Disease Research and Regulatory Science Out-of-State Care for Children on Medicaid

Read full statement >

NORD Joins Patient Organizations in Raising Concern with Kentucky Bill Proposal to Institute a State Coverage Benefit Mandate Defrayal Process

Published: Feb 27, 2024
Tagged in: Access to Affordable, Adequate Coverage

Read full statement >

NORD joins leading patient groups in urging HHS to finalize crucial rules with significant impacts on patient access

Published: Feb 26, 2024
Tagged in: Access to Affordable, Adequate Coverage

Read full statement >

NORD joins leading patient and provider groups in urging Congress to act on telehealth

Published: Feb 22, 2024
Tagged in: Telehealth

Read full statement >

NORD submits comments to CMS urging adequate reimbursement for orphan therapies in the inpatient setting

Published: Feb 21, 2024
Tagged in: Medicare, Medicaid, and Private Health Insurance Coverage

Read full statement >

NORD Supports Access to Out-of-State Telehealth Providers for Coloradans with Support of SB24-141

Published: Feb 21, 2024
Tagged in: Telehealth

Read full statement >

NORD joins 21 other patient organizations in urging the Department of Labor to rescind 2018 Association Health Plan Final Rule

Published: Feb 21, 2024
Tagged in: Access to Affordable, Adequate Coverage Medicare, Medicaid, and Private Health Insurance Coverage Short-Term, Limited-Duration Health Plans and Association Health Plans

Read full statement >

NORD joins leading patient organizations in providing comments to Florida on expanding eligibility for Children’s Health Insurance Program (CHIP)

Published: Feb 21, 2024
Tagged in: Access to Affordable, Adequate Coverage

Read full statement >

NORD’s Statement in Support for Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Published: Feb 15, 2024
Tagged in: Access to Innovative Medicines and Therapies Advancing Rare Disease Research and Regulatory Science Research

Read full statement >

NORD is Proud to Support Rare Disease Advisory Council Bill HB2758 in Arizona

Published: Feb 7, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD submits comments to NIST on 88 FR 86693, the Draft Interagency Guidance Framework for the Exercise of March-In Rights

Published: Feb 6, 2024
Tagged in: Access to Affordable Medicines

Read full statement >

NORD Supports HF2157 to Ensure Coverage of Biomarker Testing in Iowa

Published: Feb 5, 2024
Tagged in: Access to Affordable, Adequate Coverage

Read full statement >

NORD joins leading patient organizations in submitting comments to CMS on Medicaid Unwinding IFR

Published: Feb 2, 2024
Tagged in: Access to Affordable, Adequate Coverage Medicare, Medicaid, and Private Health Insurance Coverage

Read full statement >

NORD joins 24 Patient/Provider Groups in Urging the Supreme Court to Preserve FDA Authority by Reversing Fifth Circuit’s Decision in Alliance for Hippocratic Medicine et al. v FDA et al.

Published: Jan 31, 2024
Tagged in: Access to Affordable, Adequate Coverage

Read full statement >

NORD Submits Written Testimony in Support of Biomarker Coverage in Hawaii

Published: Jan 30, 2024
Tagged in: Access to Innovative Medicines and Therapies

Read full statement >

NORD Opposes Newborn Exemption Bill in Nebraska

Published: Jan 30, 2024
Tagged in: Newborn Screening

Read full statement >

NORD Submits Recommendations Relating to SB274/HB570, An Act Establishing a Prescription Drug Affordability Board (PDAB) in the Commonwealth of Virginia

Published: Jan 29, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD Submits Testimony in Response to Proposals in the NYS FY25 Executive Budget

Published: Jan 25, 2024
Tagged in: Access to Affordable Medicines Access to Affordable, Adequate Coverage

Read full statement >

NORD is Proud to Support SB 1772 for the Creation of a Rare Disease Advisory Council in Oklahoma

Published: Jan 24, 2024
Tagged in: Rare Disease Advisory Councils (RDACs)

Read full statement >

NORD submits recommendations to CMS on improving the Medicare Drug Price Negotiation Program (MDPNP) Patient Listening Sessions

Published: Jan 22, 2024
Tagged in: Access to Affordable Medicines Medicare, Medicaid, and Private Health Insurance Coverage

Read full statement >

NORD submits comments in response to Senator Cassidy’s request for information on “Improving Americans’ Access to Gene Therapies”

Published: Jan 22, 2024
Tagged in: Access to Affordable Medicines Medicare, Medicaid, and Private Health Insurance Coverage Out of Pocket Prescription Drug Costs Out-of-State Care for Children on Medicaid Value-based Pricing Assessments

Read full statement >

NORD joins 20 organizations in encouraging Congressional leadership to prioritize newborn screening programs in FY 2024 appropriations

Published: Jan 18, 2024
Tagged in: Access to Diagnostics Newborn Screening

Read full statement >

NORD Submits Comments on Federal Registrar, Volume 88, Number 198: ICD-11 Request for Information

Published: Jan 16, 2024
Tagged in: Access to Affordable, Adequate Coverage Access to Diagnostics Access to Innovative Medicines and Therapies Public Health

Read full statement >